The researches find that autoimmune disease that appears to affect men with testicular cancer. Called “testicular cancer-associated paraneoplastic encephalitis,” the disease causes severe neurological symptoms in men. Therefore They progressively lose control of their limbs, because eye movements, and, in some cases, speech. The disease begins with a testicular tumor, which appears to cause the immune system to attack the brain. Affected men often find themselves misdiagnose or undiagnos and appropriate treatment is delay.
The autoimmune disease
In a study published in The New England Journal of Medicine; the scientists identified a highly specific and unique biomarker for the disease by using a variation of “programmable phage display” technology. But Their refined version of this technology simultaneously screens more than 700,000 autoantibody targets across all human proteins.
Using this powerful tool; therefore the UCSF researchers evaluated cerebrospinal fluid from a 37-year-old man who had a history of testicular cancer and debilitating neurological symptoms; including vertigo, imbalance and slurred speech. The enhanced phage technology identified autoantibodies targeting Kelch-like protein 11 (KLHL11); which is found in the testes and parts of the brain.
These results were correlated and validated with additional patient samples from the Mayo Clinic. In addition to identifying the cause of this mysterious neurological disease; the results point the way to using this protein biomarker as a diagnostic test for men with testicular cancer-associated paraneoplastic encephalitis.
“Mayo Clinic’s Neuroimmunology Laboratory has a long history of biomarker discovery; and this continues that tradition, bringing together Mayo Clinic’s biobank, the largest repository of biospecimens in the world; with advanced technologies being devised and implemented at UCSF and CZ Biohub,” says Sean Pittock, M.D., a Mayo Clinic neurologist and corresponding author of the study. Therefore “By working together, our organizations have the potential to make biomarker discoveries much more rapidly.”
Dr. Pittock is director of Mayo Clinic’s Neuroimmunology Laboratory and the Marilyn A. Park and Moon S. Park, M.D., Director of the Center for Multiple Sclerosis and Autoimmune Neurology. Because Mayo Clinic’s Neuroimmunology Laboratory annually screens about 150,000 patients for autoimmune neurological diseases by applying patients’ biospecimen samples serum or cerebrospinal ?uid to thin slices of brain tissue from mice.
Some patients with autoimmune neurological diseases harbor antibodies that bind to tissue with a specific pattern of staining. Therefore About 20 years ago, Mayo scientists first identified a staining pattern that researchers dubbed “sparkles” because, in a darkroom under a microscope, because the patient’s sample looked like stars shining dimly in the night sky, Dr. Pittock says. Because The male patient had ataxia poor coordination, involuntary eye movements, change in speech and turned out to have testicular cancer.
History of biomarker discovery
Over the years, the Mayo lab occasionally identified the sparkles pattern, and the patients’ clinical stories were the same: ataxia and testicular cancer. But the pattern was faint and easy to miss, and an auto antibody target remained elusive. Therefore A UCSF team led by Joe DeRisi, Ph.D., a biochemist and co-president of Chan Zuckerberg Biohub, and Michael Wilson, M.D., neurologist and member of the UCSF Weill Institute for Neurosciences.